ERBB2 and breast cancer: Withaferin has been shown to reduce tumor growth and metastasis in various preclinical models of breast cancer such as MMTV-neu mice (representing ER− disease) and MNU-induced rat models (representing ER+ disease) without observable systemic toxicity [138].